2021 Genitourinary Cancers Symposium | Supplements And Featured Publications

Cabozantinib Significantly Prolongs PFS Over Sunitinib in Papillary RCC

February 14, 2021

February 13, 2021 - Cabozantinib resulted in a statistically significant and clinically meaningful prolongation of progression-free survival compared with sunitinib in patients with metastatic papillary renal cell carcinoma.

Frontline Nivolumab/Cabozantinib Maintains Survival Benefit Over Sunitinib in Advanced RCC

February 13, 2021

February 12, 2021 - The combination of nivolumab and cabozantinib continued to showcase a superior survival benefit over single-agent sunitinib when used as first-line treatment in patients with advanced renal cell carcinoma.

Lenvatinib Plus Pembrolizumab Improves Survival, Responses Versus Sunitinib in Advanced RCC

February 13, 2021

February 13, 2021 - Lenvatinib in combination with pembrolizumab resulted in improved overall survival, progression-free survival, and objective response rate over sunitinib in the frontline treatment of patients with advanced renal cell carcinoma.

Tivozanib Reduces Symptomatic Burden and Toxicity in RCC

February 12, 2021

February 12, 2021 - Tivozanib led to a significantly greater quality-adjusted time without symptoms of disease and toxicity as third- or fourth-line therapy versus sorafenib in patients with metastatic renal cell carcinoma.

Frontline Immunotherapy Correlates With Improved OS Over TKIs in Advanced Non–Clear Cell RCC

February 11, 2021

February 11, 2021 - First-line treatment with immune checkpoint inhibitor–based regimens could be linked with an improvement in overall survival versus select targeted therapies in patients with metastatic non–clear cell renal cell carcinoma.

Lenvatinib Plus Everolimus Safe, Effective Following Immunotherapy in Clear Cell RCC

February 11, 2021

February 11, 2021 - Lenvatinib in combination with everolimus has proven to be safe and effective when used in the treatment of patients with clear cell renal cell carcinoma who had previously received an immune checkpoint inhibitor.

x